SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001062993-21-004144
Filing Date
2021-05-05
Accepted
2021-05-05 16:15:20
Documents
2
Period of Report
2021-04-28

Document Format Files

Seq Description Document Type Size
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.html 3  
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.xml 3 1536
2 EXHIBIT 24 exhibit24.htm EX-24 7207
  Complete submission text file 0001062993-21-004144.txt   10151
Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
Myers Scott Dunseth (Reporting) CIK: 0001356256 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36596 | Film No.: 21893439

Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Issuer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations